← Leaderboards
Michael Einer Hibbing
Fimbrion Therapeutics, Inc.
$450,000
Attributed
$900,000
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $300K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$900,000 · 2
By mechanism
R43$900,000 · 2
Top collaborators
- Laurel Mcgrane3 shared
Most similar at Fimbrion Therapeutics, Inc.
Same institution · by research overlap
- Thomas Joseph Hannan$6,586,896
- Laurel McGrane$750,000
- Zachary Cusumano$300,000
Others in their field
Other Rising Stars on “Half-Life”
- Robert W Cross · University Of Texas Med Br Galveston$4,640,498
- C.k. Osborne · Leidos Biomedical Research, Inc.$3,516,733
- Jacob Glanville · Centivax Inc$2,987,953
- Nam-Joon Cho · Stanford University$2,909,919
- Andrew Barrett · Cessation Therapeutics, Llc$2,612,736
- Lawrence J Zana · Consegna Pharma, Inc.$2,545,988
Research focus
Half-LifeInnovationComplexDrug KineticsImmuneInfectionCollaborationsCommercial ApplicationDesignDrug DesignCellsAffinityBacteriaAntibiotic ResistanceAntibioticsBindingCombatBiological AvailabilityAntimicrobialAntagonistAntimicrobial ResistanceDoseAnti-Bacterial AgentsIn Vitro
Grant awards (3)
Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections$300,000
R43 · FY2025 · AI · contact PI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections$300,000
R43 · FY2024 · AI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections$300,000
R43 · FY2023 · AI